Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 174   

Articles published

PFE 34.53 +0.37 (1.08%)
price chart
Pfizer Inc. (PFE)'s Stock May Outperform in 2015-Here's Why
Pfizer Inc. (NYSE:PFE) has seen its earnings and revenue plummet during the last several years as generic drug makers invaded the market with their lower priced alternatives.
Stock to Follow: Pfizer Inc. (NYSE:PFE)  Street Report
Morning Hot : AK Steel Holding Corporation (AKS), Pfizer Inc. (PFE ...  WallStreet Scope
Why Pfizer Inc. Isn't Built to Last
In its recent investor presentation, Pfizer's management prepped investors for a major shakeup, stating that they are "establishing the groundwork required to operationalize a potential split of the company". Soon thereafter, Pfizer announced the $17 ...
Pfizer Inc, Eli Lilly, AstraZeneca plc and Bristol-Myers Squibb See Increase ...
The prescription data by Symphony Health, complied by Bloomberg analysts, Michael Shah and Sam Fazeli, shows impressive growth in sales of the drugs manufactured by US pharmaceutical giants including Pfizer Inc. (NYSE:PFE), Eli Lilly & Co.
Did Pfizer Inc. Just Gut Its Chances of Finding New Blockbusters?
Pfizer Inc. (NYSE: PFE ) and other big drugmakers have a problem on their hands. Facing a steady stream of patent expirations on top-selling medicines, they're caught in a tug-of-war between developing next-generation therapies and cutting costs to ...
First Call Rating Update on Pfizer, Inc.  Stafford Daily
Pfizer Lifted to Hold at Vetr Inc. (PFE)  The Legacy
Tuesday's Vital Data: Ford Motor Company (F), Pfizer Inc. (PFE) and Herbalife ...
Shares of blue-chip pharmaceutical firm Pfizer jumped more than 2% on Monday, after the company announced that it was resuming late-stage trials its chronic pain drug tanezumab, which is being co-developed with Eli Lilly and Co.
Pfizer Inc, Eli Lilly To Recommence Phase 3 Trials For Pain Drug Tanezumab
Leading pharmaceutical companies Pfizer Inc. (NYSE:PFE) and Eli Lilly and Co (NYSE:LLY) announced Monday their plan to recommence final stage studies for pain drug Tanezumab, after the US Food and Drug Administration decided to lift the partial hold ...
Pfizer, Lilly to Resume Studies of Pain Treatment Tanezumab  Wall Street Journal
Pfizer, Lilly to resume study testing pain drug  Reuters
Better Dividend Stock: Pfizer Inc. vs. Bristol-Myers Squibb Co.
To make a long story short, we will probably see Pfizer split into two companies in the near future. Specifically, the Street is expecting Hospira to be paired with the company's legacy products, allowing the drugmaker to unlock the value of its new ...
Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb Co. (NYSE:BMY); Which ...  WallStreet.org
Healthcare Most Active : Bristol-Myers Squibb Company (NYSE:BMY), Johnson ...  eMarketsDaily
Superconductor Technologies, Inc. (SCON), Pfizer Inc. (PFE), ACADIA ...
Hal Mintz's Sabby Capital has initiated a passive stake in Superconductor Technologies, Inc. (NASDAQ:SCON) according to a schedule 13G form filed with the SEC.
Pfizer Pushes Through Key Resistance Level
Pfizer Inc. (NYSE: PFE) shares were trading sharply higher by $0.95 (2.8 percent) at $35.20 in Monday's session. The catalyst for the rally may be a price target increase by Jefferies, which bumped its target from $42 to $45.
Pfizer (PFE) Is The 'Chart of the Week'
After absorbing some very big acquisitions over the years, Pfizer became a stodgy old company whose returns barely kept pace with the market.
Most Active Mid Cap Mover- Pfizer Inc. (NYSE:PFE) Pepsico, Inc. (NYSE:PEP ...  StreetWise Report
Pfizer Cut to "Sell" at Vetr Inc. (PFE)  sleekmoney